Extending shelf life of dithiothreitol-treated panel RBCs to 28 days.
Daratumumab (DARA) causes non-specific results in indirect agglutination testing (IAT). Dithiothreitol (DTT) treatment of panel red blood cells (RBCs) abolishes DARA interference. The objective of our study was to extend stability of DTT-treated panel RBCs to 28 days through application of a commercially available panel RBC stabilizer. Serological antigen typing and IAT using DARA sera and DARA plasma spiked with weakly reacting alloantibodies was performed up to 28 days after DTT treatment and stabilization. DTT treatment resulted in loss of Fy-antigen expression on some panel RBCs. Antigen profiles of stabilized, DTT-treated panel RBCs remained stable. Alloantibodies in DARA sera and DARA plasma were reliably detected. Application of a commercially available RBC stabilizer extends shelf life of DTT-treated panel RBCs to 28 days.